Pharmacogenomics (PGx), which considers the relationship between an individual’s genetics and their response to medications (i.e., drug-gene interactions), is expanding in clinical medicine. There are currently 25 evidence-based guidelines covering…
Read More
What is Cell & Gene Therapy? Genes are defined by the NIH as the “basic physical and functional unit of heredity.” We receive these valuable sequences of DNA from our…
Read More
Clinical trials require a unique approach to public dissemination. Because clinical trials often involve the collection of sensitive information, sharing clinical trial data should always be conducted through formal and…
Read More
During the current COVID-19 pandemic, it is important to find strategies to keep your drug development program moving forward. With many studies now paused, cancelled completely, or in the early…
Read More
If you missed our live panel discussion on how the drug development industry is being impacted by the COVID-19 pandemic, we have assembled this post to highlight some of the…
Read More
To formally request approval to market a new drug in the United States, sponsors must submit either a New Drug Application (NDA) or a Biologics License Application (BLA) to the…
Read More
A fundamental question for any drug development program is which regulatory pathway to pursue. The answer is important to determine early on, because it dictates the scope of clinical and…
Read More